ACCESS Newswire
10 Sep 2019, 17:49 GMT+10
MUNICH/MARTINSRIED, GERMANY / ACCESSWIRE / September 10, 2019 / Secarna Pharmaceuticals ('Secarna'), a new breed of biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets, today announced that the Company has entered into an research agreement with a global pharmaceutical company to support research and discovery in the field of oncology. Under the terms of the agreement, the global top 10 pharmaceutical partner will utilize ASOs derived from Secarna's proprietary LNAplusTM platform in support of anti-cancer therapies the partner is developing and commercializing. Financial terms and the name of the partner were not disclosed. The LNAplusTM platform has been validated through numerous internal projects as well as multiple academic and industry collaborations such as with Firebrand Therapeutics, Lipigon Pharmaceuticals, and Met P Pharma.
'This first agreement with a large global pharmaceutical partner is a major milestone for Secarna and a crucial step in paving the path for a new generation of anti-cancer therapeutics,' said Jonas Renz, Managing Director and Co-founder of Secarna Pharmaceuticals. 'The agreement is a further testament to our LNAplusTM approach of developing highly specific, safety-optimized and efficacious antisense oligonucleotide therapies for challenging targets.'
About Secarna's Proprietary Drug Discovery Platform, LNAplusTM
Secarna's proprietary third-generation antisense oligonucleotide (ASO) platform, LNAplusTM, which encompasses all aspects of drug discovery and pre-clinical development, enables the Company to discover novel antisense-based therapies for challenging or currently undruggable targets.Secarna's platform and ASOs have previously been validated by numerous in-house projects as well as in several academic and industry collaborations. With over 15 development programs focusing on targets and indications such as immuno-oncology, immunology, antiviral, fibrotic diseases, ophthalmology, neurodegenerative diseases and cardiometabolic diseases, where antisense-based approaches have clear benefits compared to other therapeutic modalities, Secarna is the leading European antisense drug discovery and development company.
About Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company with multiple innovative antisense therapies in various stages of pre-clinical development in the areas of immuno-oncology, ophthalmology, immunology, fibrotic diseases (airways, liver, kidney), and anti-viral applications. Secarna's mission is to maximize the performance and output of its proprietary LNAplusTM antisense oligonucleotide platform to develop highly specific, safe, and efficacious antisense therapies for challenging or currently not druggable targets. www.secarna.com
Contact:
Jonas Renz
Managing Director and Co-founder
[email protected]
Secarna Pharmaceuticals GmbH & Co. KG
Am Klopferspitz 19
82152 Planegg/Martinsried
Tel.: +49 (0)89 215 46 375
For media enquiries:
Anne Hennecke
MC Services AG
[email protected]
Tel.: +49 (0)211.52 92 52 22
The issuer is solely responsible for the content of this announcement.
SOURCE: Secarna Pharmaceuticals GmbH & Co. KG
Get a daily dose of Orange County Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Orange County Sun.
More InformationCULVER CITY, California: TikTok is preparing to roll out a separate version of its app for U.S. users, as efforts to secure a sale...
WASHINGTON, D.C.: President Donald Trump claimed he was unaware that the term shylock is regarded as antisemitic when he used it in...
NEW YORK, New York - Monday's trading session saw mixed performances across U.S. and global markets, with several major indices posting...
OMAHA, Nebraska: With Congress considering cuts totaling around US$1 trillion to Medicaid over the next decade, concerns are rising...
WASHINGTON, D.C.: The U.S. government has granted GE Aerospace permission to resume jet engine shipments to China's COMAC, a person...
MILAN, Italy: Italian regulators have flagged four non-EU countries—including Russia—as carrying systemic financial risk for domestic...
CULVER CITY, California: TikTok is preparing to roll out a separate version of its app for U.S. users, as efforts to secure a sale...
WASHINGTON, D.C.: President Donald Trump claimed he was unaware that the term shylock is regarded as antisemitic when he used it in...
PARIS, France: A strike by French air traffic controllers demanding improved working conditions caused significant disruptions during...
OMAHA, Nebraska: With Congress considering cuts totaling around US$1 trillion to Medicaid over the next decade, concerns are rising...
ROME, Italy: Quick thinking by emergency responders helped prevent greater devastation after a gas station explosion in southeastern...
WASHINGTON, D.C.: President Donald Trump is drawing praise from his core supporters after halting key arms shipments to Ukraine, a...